The Company continues to believe in the potential of its flagship product, Tarceva, to become a major product in the treatment of human cancer. The Company noted that Tarceva is the only EGFR inhibitor to have demonstrated a survival benefit in non-small cell lung cancer (NSCLC) and is only the second drug of any kind to have shown a survival benefit in pancreatic cancer. The FDA approved Tarceva for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen after a review lasting just 3.5 months. The Company further noted that today's announcement by a competitor that its EGFR inhibitor had failed to demonstrate a survival benefit in NSCLC is consistent with the Company's previously stated beliefs that Tarceva is differentiated from the competition and well positioned to rapidly emerge as the leading EGFR inhibitor in the treatment of human cancer.

About OSI Pharmaceuticals

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of clinical trials, the FDA review process and other governmental regulation, OSI's and its collaborators' abilities to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission.